许多临床研究表明糖尿病性视网膜病变(diabetic retinopa-thy,DR)的发病机制与血管内皮生长因子(vascular endo-thelial growth factor,VEGF)有关,VEGF抑制剂主要通过与VEGF结合并阻断其生物活性而起作用。目前在DR新生血管形成及血管渗漏的治疗中取得了显著的成绩。我们对VEGF抑制剂的分类、作用机制、安全性以及治疗DR的相关应用进展作一综述。

Many clinical studies have implicated the importance of vascular endothelial growth factor (VEGF) in the pathogenesis of diabetic retinopathy(DR). VEGF inhibitors were combined with VEGF molecules to counteract its function. There are achievements in the therapy for treating neovascularization and vascular leak-age of DR. This article makes a review in the classification,mechanism of function,safety as well as applied development of VEGF inhibitors for DR.